1. Home
  2. SNTI vs HGBL Comparison

SNTI vs HGBL Comparison

Compare SNTI & HGBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNTI
  • HGBL
  • Stock Information
  • Founded
  • SNTI 2016
  • HGBL 1937
  • Country
  • SNTI United States
  • HGBL United States
  • Employees
  • SNTI N/A
  • HGBL N/A
  • Industry
  • SNTI Biotechnology: Pharmaceutical Preparations
  • HGBL Business Services
  • Sector
  • SNTI Health Care
  • HGBL Consumer Discretionary
  • Exchange
  • SNTI Nasdaq
  • HGBL Nasdaq
  • Market Cap
  • SNTI 85.3M
  • HGBL 72.3M
  • IPO Year
  • SNTI N/A
  • HGBL N/A
  • Fundamental
  • Price
  • SNTI $3.38
  • HGBL $2.07
  • Analyst Decision
  • SNTI Strong Buy
  • HGBL Strong Buy
  • Analyst Count
  • SNTI 1
  • HGBL 1
  • Target Price
  • SNTI $12.00
  • HGBL $4.00
  • AVG Volume (30 Days)
  • SNTI 226.4K
  • HGBL 60.7K
  • Earning Date
  • SNTI 05-06-2025
  • HGBL 05-08-2025
  • Dividend Yield
  • SNTI N/A
  • HGBL N/A
  • EPS Growth
  • SNTI N/A
  • HGBL N/A
  • EPS
  • SNTI N/A
  • HGBL 0.14
  • Revenue
  • SNTI N/A
  • HGBL $45,361,000.00
  • Revenue This Year
  • SNTI N/A
  • HGBL $10.82
  • Revenue Next Year
  • SNTI N/A
  • HGBL $15.17
  • P/E Ratio
  • SNTI N/A
  • HGBL $14.29
  • Revenue Growth
  • SNTI N/A
  • HGBL N/A
  • 52 Week Low
  • SNTI $1.52
  • HGBL $1.52
  • 52 Week High
  • SNTI $16.94
  • HGBL $2.74
  • Technical
  • Relative Strength Index (RSI)
  • SNTI 45.79
  • HGBL 37.80
  • Support Level
  • SNTI $3.10
  • HGBL $1.96
  • Resistance Level
  • SNTI $3.50
  • HGBL $2.07
  • Average True Range (ATR)
  • SNTI 0.39
  • HGBL 0.07
  • MACD
  • SNTI -0.07
  • HGBL 0.00
  • Stochastic Oscillator
  • SNTI 20.36
  • HGBL 0.00

About SNTI Senti Biosciences Inc.

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

About HGBL Heritage Global Inc.

Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.

Share on Social Networks: